Printable Program



April 11-13, 2019

Fort Lauderdale, FL


Thursday, April 11, 2019


9:00 - 10:30 AMGreat Hall 1-3
Welcome Coffee Break

9:00 - 5:00 PMGreat Hall Foyer
Registration

10:30 - 10:45 AMGreat Hall 4
Welcome

Chair(s): Eva Kline-Rogers, Renato Lopes, and Sara Vazquez (Conference Co-Chairs)
10:45 - 12:30 PMGreat Hall 4
Session 1 Rapid Fire - What's New Since the Last ACF Conference?

Chair(s): Mark Crowther and Terri Schnurr
10:45
Top Papers From The Last Year You Need To Know About
Tracy Minichiello
University of California, San Francisco

11:20
New Antithrombotic Agents
Deborah Siegal
McMaster University

11:55
Guidance Updates From Ash And Acc
Daniel Witt
University of Utah College of Pharmacy

12:30 - 2:00 PMGreat Hall 5
BMS/Pfizer Lunch Symposium: Clinical Trial Results Complemented by a Real-World Database Analysis of a Medicare Nonvalvular Atrial Fibrillation (NVAF) Population

12:30 - 2:00 PMGreat Hall 6
Janssen Lunch Symposium: Advances in the Management of CAD/PAD: A new treatment for thrombotic risk reduction

2:15 - 4:00 PMGreat Hall 4
Session 2 Combined Therapy - AFib, Coronary and Peripheral Disease

Chair(s): Elaine Hylek and Alan Jacobson
2:15
Anticoagulants For Secondary Prevention Of Cad/Pad
John Eikelboom
McMaster University

2:50
What Is Pad And How Should I Treat It?
Heather Gornik
Cleveland Clinic

3:25
Combined Antithrombotic Therapy: Is There A Role For It In 2019?
Renato Lopes
Duke University

4:00 - 5:30 PMGreat Hall 1-3
Poster Presentation and Welcome Reception

P1
Description Of Anticoagulation Use, Risk Factors And Patient Population In A Pharmacist Managed Anticoagulation Clinic In Rural, Western Kenya.
John Kanyi1, Sara Fletcher2, Sarah Kipkulei3, Shirley Boit1, Samuel Nyanje4, Everton Wanakacha4, Elvis Aswani4, Emily Deremiah2, Madeleine Ochs2, Emily Buatois2, Imran Manji1, Rakhi Karwa2, Sonak D Pastakia2
1Moi Teaching & Referral Hospital, Eldoret, Kenya, 2Purdue University College of Pharmacy, Indiana, IN, United States, 3Moi Teaching & Referral Hospital College of Health Sciences, Eldoret, Kenya, 4Academic Model Providing Access To Healthcare (AMPATH), Eldoret, Kenya

P2
Improving Access, Quality And Cost With Centralized Anticoagulation Services Hub: Service Establishment And Workflow
Megan Grischeau, Melissa Fontana, Andrea Mendyk, Dana Frank, Sandra Hedin
VHA - VISN 12, Hines, IL, United States

P3
Integration Of Direct Oral Anticoagulation Care Into A Traditional Warfarin Clinic: A Single Academic Center Experience And Pilot Study
Pamela Burgwinkle, MS,NP-C,1, Patricia Shreve, DNP, APRN1, David McManus, MD1,2, Brian Smith, PharmD1, Sarah Nadeau, CPHT1, Jaclyn Piche, RN, BSN1
1Umassmemorial Hospital, Worcester, MA, United States, 2University of Massachusetts Medical School, Worcester, MA, United States

P4
Impact Of A Direct Oral Anticoagulant Population Management Tool On Anticoagulation Therapy Monitoring In Clinical Practice
Daniela Valencia1, Patrick Spoutz2, Jaclyn Stoppi1, Jeffery L Kibert3, Arthur Allen4, David Parra5,6, Augustus Hough 1
1West Palm Beach VA Medical Center, West Palm Beach, FL, United States, 2Kansas City VA Medical Center, Kansas, MO, United States, 3William Jennings Bryan Dorn VA Medical Center, Columbia, SC, United States, 4Salt Lake City VA Medical Center, Salt Lake , UT, United States, 5Veterans Integrated Service Network 8, Pharmacy Benefits Management, Bay Pines , FL, United States, 6Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Mineapolis, MN, United States

P5
Evaluation Of Rivaroxaban Prescription Adherence Rates Compared To Warfarin For Venous Thomboembolism At A Large Teaching Hospital 
Desire' L. Outler1, Sweta M. Patel1,2, Jennifer B. Elliott1,2, Michael D. Knauss2, Mikhail Y. Akbashev3
1Mercer University College of Pharmacy, Atlanta, GA, United States, 2Grady Health System, Atlanta, GA, United States, 3Emory University School of Medicine, Atlanta, GA, United States

P6
Telehealth: A New Innovative Approach In Anticoagulation Management
Maria Vega, ANP-BC 1, Libiny John,FNP-BC2, Susan Sciortino,FNP-BC2, Elise Arambages, FNP-BC2, Danielle Auletta, MPA1, Ilias Nickolakopoulos, MD3, Alex Spyropoulos, MD1,2,3,4
1Northwell Health at Lenox Hill Hospital, NY, NY, United States, 2Northwell Health at Staten Island University, Staten Island, NY, United States, 3Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States, 4Center for Health Innovations and Outcomes Research - The Feinstein Institute for Medical Research, Manhasset, NY, United States

P7
Monitoring Direct Oral Anticoagulants Using A Dashboard Model Versus Standard Care In A Federal Health Care Setting
Suzanne T. Chau
Captain James A. Lovell Federal Health Care Center, North Chicago, IL, United States

P8
Evaluation Of Appropriate Prescribing And Management Of Direct Oral Anticoagulants (Doacs) In Internal Medicine And Cardiovascular Clinics And The Feasibility Of Expanding Current Pharmacist-Provided Outpatient Anticoagulation Services.
Ashley Yarabinec1, Margaret Castelli1, Brittany Rosenfeld1, Nancy Kablack1, Cynthia Wessel1, Nicole Handlow1, Lindsey Jachim1, Swana Thomas1, Nicole Modany1, Andrew Bever2, Caroline Dillon2, Michael Hagerty1, Paula Horn1
1Allegheny General Hospital Department of Pharmacy Services, Pittsburgh, PA, United States, 2Duquesne University School of Pharmacy, Pittsburgh, PA, United States

P9
Analysis Of Quality Measures Before And After Switching Care Models In Maqi2 Anticoagulation Clinics.
Joseph Maniaci1, Constantina Alexandris-Souphis1, Helen Gikas2, Mona Ali3, Scott Kaatz2, Brian Haymart1, Nannette Gearhart3, Mary DeYoung4, Stacy Ellsworth2, Jim Froehlich1, Geoff Barnes1, Eva Kline-Rogers1, Noelle Ryan2
1University of Michigan, Ann Arbor, MI, United States, 2Henry Ford Health System, Detroit, MI, United States, 3Beaumont Health System, Royal Oak, MI, United States, 4Spectrum Health, Grand Rapids, MI, United States

P10
Evaluation Of A Direct Oral Anticoagulation (Doac) Stewardship Program: Analysis Of A Drug Consult Review Process And Population Based Management Tool
Carli Smith, Haley Henry, Bishoy Ragheb, Ashley Thomas, Jennifer Baker
VA Tennessee Valley Healthcare System, Murfreesboro, TN, United States

P11
Measuring The Impact Of A Pharmacist-Managed Direct Oral Anticoagulant Service
Katie Xu, Aaron Dush, H.Paige Erdeljac, Stephanie Yager, Tzu-Fei Wang
The Arthur G James Cancer Hospital and Richard J Solove Research Institute at The Ohio State University, Columbus, OH, United States

P12
Pharmacists As Front Line Clinicians In A New Multidisciplinary Thrombosis Service
Stephanie Young1,2, Rachel Ward1, Rufaro Chitsike2,1
1Memorial University, St. John's, NL, Canada, 2Eastern Health Regional Health Authority, St. John's, NL, Canada

P13
Patient Satisfaction With Warfarin Therapy On Extended International Normalized Ratio Follow-Up Intervals 
Andrea Porter1,2, Rebecca Schoen3, Michael Nagy4, Amanda Margolis1,2
1University of Wisconsin-Madison School of Pharmacy, Madison, WI, United States, 2William S. Middleton Memorial Veterans Hospital, Madison, WI, United States, 3Texas Tech University Health Sciences Center, Dallas, TX, United States, 4Medical College of Wisconsin Pharmacy School, Milwaukee, WI, United States

P14
Evaluation Of Anticoagulation In Patients With Atrial Fibrillation Admitted With Acute Ischemic Stroke
Brian Carlone, Elizabeth LaRose, Joleen Bierlein, Stephen Rolfe, Wesley Zemrak
Maine Medical Center, Portland, ME, United States

P15
The Impact Of Cyp2C19 Genetic Mutation And Non-Genetic Factors On The Incidence Of Major Adverse Cardiovascular Events  In Patients Treated With Clopidogrel In Qatar
Zainab Ali1, Loulia Bader1, Dania Al-Masri1, Mariam Ali2, Salah Arafa2, Abdulrahman Arabi2, Shaban Mohammed2, Nasser Rizk3, Fatima Mraiche1, hazem Elewa1,2
1College of Pharmacy, Doha, Qatar, 2Hamad Medical Corporation, Doha, Qatar, 3College of Health Science, Doha, Qatar

P16
When Less Is More:  An Anticoagulation Service Initiative To Target Combination Antithrombotic Therapy
Christina Meadows1, Arthur Allen2
1VA Salt Lake City Health Care System, Salt Lake City, UT, United States, 2VA Salt Lake City Health Care System, Salt Lake City, UT, United States

P17
Real World Safety Analysis Of Combined Single Antiplatelet And Anticoagulant Therapy In Patients With Atrial Fibrillation.
Stephanie Tran1, Patrick Klem1,2, Kerry Schwarz2, Toby Trujillo1,2
1University of Colorado , Aurora, CO, United States, 2University of Colorado Hospital, Aurora, CO, United States

P18
Direct Oral Anticoagulation Plus Antiplatelet Therapy: Prescribing Rates And Bleeding Outcomes
Tyler T. Tinkham1, Sara R. Vazquez1,2, Aubrey E. Jones1,2, Daniel M. Witt1,2
1University of Utah, Salt Lake City, UT, United States, 2Thrombosis Service, University of Utah Health, Salt Lake City, UT, United States

P19
Direct Oral Anticoagulant Versus Warfarin For Deep Vein Thrombosis/ Pulmonary Embolism: A Comparison Of Cost, Reimbursement, And Length Of Stay
Zachary Robinson 1, Stephanie Cailor2, Joseph Metz1
1Premier Health , Dayton, OH, United States, 2Dayton V.A., Dayton, OH, United States

P20
Comparison Of Two Intravenous Unfractionated Heparin Dosing Strategies: Aptt And Anti-Xa Monitoring
Nicole Free, Becky Szymanski, Tina Hipp, Nigel Rozario
Carolinas HealthCare System NorthEast, Concord, NC, United States

P21
Evaluation Of Safety And Efficacy Of Direct Oral Anticoagulants In The Treatment Of Heparin-Induced Thrombocytopenia 
Alina Kukin, Amanda Liszewski, Surabhi Palkimas
University of Virginia Health System, Charlottesville, VA, United States

P22
Challenges Of Converting To Anti-Xa Monitoring Of Iv Unfractionated Heparin In An Oral Factor Xa Inhibitor Era
Van Q. Pham, Linh L. Chan, Walter L. Crumpler, Anita Wang, Alan K. Jacobson
VA Loma Linda HCS, Loma Linda, CA, United States

P23
Appropriateness Of Blood Concentrations Of Direct Oral Anticoagulants In Patients At High Risk Of Under Or Over Exposure
Olga Sherman, Diana Otero, Lawrence Baruch
James J Peters VAMC, Bronx, NY, United States

P24
Description Of Anti-Xa Monitoring Practices During Low Molecular Weight Heparin Use
Albert Lin, Sara Vazquez, Aubrey Jones, Daniel Witt
University of Utah College of Pharmacy, Salt Lake City, UT, United States

P25
Anticoagulant Lab Panel For Emergent Reversal Of Apixaban And Rivaroxaban
Kimberly Hodulik, Adam Root, Maria Notini, Charles Stewart, Thomas Ortel
Duke Hospital, Durham, NC, United States

P26
Direct Oral Anticoagulant Drug Level Testing:  Experience From An Outpatient Anticoagulation Clinic
Krista Luck, Kristin Duffey, Sara Iacono
Mission Hospital, Asheville, NC, United States

P27
Anti-Factor Xa Ordering Practices For Apixaban And Rivaroxaban Within An Academic Medical Center
Anne Rose, David Ciske, Erin Robinson, Eliot Williams
UW Health , Madison, WI, United States

P28
Higher Oral Anticoagulation Knowledge (Oak)Score At Baseline Associated With Better Time In Therapeutic Range(Ttr) In Patients Taking Warfarin
Constantina Alexandris-Souphis1, Delaney Feldeisen1, Brian Haymart1, Xiaokui GU1, Stephanie Watts2, Renee Kozlowski2, Jay Kozlowski2, James Froehlich1, Geoff Barnes1, Eva Kline-Rogers1
1Michigan Medicine/MCORRP, Ann Arbor, MI, United States, 2Huron Valley Hospital/Cardiology and Vascular Associates PC, Commerce, MI, United States

P29
Preferences For After-Visit Summaries: An Analysis Of How Patients Prefer To Receive Their After-Visit Summary From The Anticoagulation Management Clinic At Cone Health Internal Medicine Center
Abu S. Azad1, Jennifer J. Kim1,2, James B. Groce2,3
1UNC Eshelman School of Pharmacy , Chapel Hill, NC, United States, 2Cone Health, Greensboro, NC, United States, 3Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, United States

P30
Assessing Patient Preferences For Switching To Direct Oral Anticoagulants
Jack N. Wright, Sara R. Vazquez, Aubrey E. Jones, Kibum Kim, Daniel M. Witt
University of Utah College of Pharmacy, Salt Lake City, UT, United States

P31
Reduction Of Ed Visits For Epistaxis In Patients Taking Coumadin After A Patient Education Program
Constantina Alexandris-Souphis, Brian Haymart, Delaney Feldeisen, Xiaowen Kong, Rebecca Harvey, Melissa Pynnonen, James Froehlich, Eva Kline-Rogers, Geoffrey Barnes
Michigan Medicine/MCORRP, Ann Arbor, MI, United States

P32
Transitioning Patients To Warfarin Self-Management Using A Computer-Based Home Monitoring Model With Point Of Care Testing
Samer Makhaly, Lissa Ajjamada, Tanya Sakamene, Kim Ma, Susan Solymoss
McGill University Health Center, Montreal, QC, Canada

P33
Point-Of-Care Vs Venipuncture International Normalized Ratio Testing In Adult Patients With Ventricular Assist Devices At A Large Tertiary Academic Medical Center
Amy Levesque1, Katelyn Sylvester1, Jean Connors2
1Brigham and Women's Hospital, Department of Pharmacy Services, Boston, MA, United States, 2Brigham and Women's Hospital, Division of Hematology, Boston, MA, United States

P34
Interruption Of Warfarin For Low-Risk Procedures
Austin Foote1, Brian Haymart1, Xiaowen Kong1, Mona Ali2, Scott Kaatz3, Eva Kline-Rogers1, Jay Kozlowski4, Tina Alexandris-Souphis1, James B. Froehlich1, Geoffrey D. Barnes1
1University of Michigan, Ann Arbor, MI, United States, 2Beaumont Hospital, Royal Oak, MI, United States, 3Henry Ford Hospital, Detroit, MI, United States, 4Huron Valley-Sinai Hospital, Commerce, MI, United States

P35
Post-Procedure Warfarin Resumption Dosing Strategies And Related Outcomes In Patients Bridged With Enoxaparin
Maria Goldman, Stacy Ogle
Carroll Hospital , Wesminster, MD, United States

P36
Warfarin Managment For Arterial Thromboembolism Originating From Extracardiac Source At A Veteran Affairs Medical Center
Jiji Thomas, Tiffany Boelke, Rachel Barr
Richard L Roudebush Veteran Affairs Medical Center, Indianapolis, IN, United States

P37
Implementation Of An Anticoagulation Quality Metrics Reporting Program Using The Electronic Health Record Across A Large Academic Medical System
Lisa Moherman1, Valerie Moyer1, Joshua Koenig1, Briana Kocher1, Stephanie Iyer2, Daniel O'Neil1
1WVU Medicine, Morgantown, WV, United States, 2UNC Health Care, Chapel Hill, NC, United States

P38
Need Assessment Of Establishing Pharmacist Managed Anticoagulation Clinic At Tikur Anbessa Specialized Hospital: Quality Improvement Study
Tamrat Assefa1, Asmamaw Yenesew1, Girma Eshetu1, Nuredin Shiferaw1, Minyahil Alebachew1
1Addis Ababa University, Addis Ababa, Ethiopia, 2Addis Ababa University, Addis Ababa , Ethiopia, 3Addis Ababa University, Addis Ababa, Ethiopia, 4Addis Ababa University, Addis Ababa, Ethiopia, 5Addis Ababa University, Addis Ababa , Ethiopia

P39
Impact Of Implementation Of An Antithrombin Replacement Guideline In A Pediatric Institution
Ying Lee1, Anh Hoang1, Caitlin Le1, Courtney Long1, Ayesha Zia2
1Children's Health , Dallas, TX, United States, 2UT Southwestern Medical Center, Dallas, TX, United States

P40
Optimizing Anticoagulation For Patients With Low Time-In-Therapeutic Range
Naomi Yates, Alex Kilgore
Kaiser Permanente, Atlanta, GA, United States

P41
Pharmacist-Led Intervention To Address Patients With Atrial Fibrillation Not Receiving Anticoagulation
Tachanda M. Mensah, Naomi Y. Yates
Kaiser Foundation Health Plan of Georgia, Inc., Atlanta, GA, United States

P42
Retrospective Evaluation Of The Use Of Proton Pump Inhibitors In Patients On Concomitant Anticoagulant And Antiplatelet Therapy
Tanvi Patil PharmD, BCPS, Kimberly Murphy, PharmD, Laura Woodard, PharmD, Morgan Lebrecht, PharmD
Veterans Health Administration, Salem, VA, United States

P43
Assessing Knowledge And Practice Of Hospital And Community Pharmacists Towards Direct Oral Anticoagulants (Doacs) In Qatar
ahmed El-Bardissy1, Shaban Mohammed1, Ahmed Shible1, Rizwan Imanullah1, Abdul Moqeeth Mohammed1, hazem Elewa1, 2
1Hamad Medical Corporation, Doha, Qatar, 2Qatar University, Doha, Qatar

P44
Aspirin And Warfarin: A Combination For Everyone?
Katherine Huang1, Vinay Shah1, Syed Ahsan1, Scott Kaatz1, Greg Krol1, Stacy Ellsworth1, Noelle Ryan1, Jeremy Gentile1, Brandon Wilkinson2
1Henry Ford Health System, Detroit, MI, United States, 2Wayne State University School of Medicine, Detroit, MI, United States

P45
Us Emergency Department Visits For Oral Anticoagulant-Related Bleeding, 2017
Andrew I. Geller1, Daniel S. Budnitz1, Kathleen O. Rose2, Nina J. Weidle3, Sandra K. Goring2, Ruth N. Moro2, Maribeth C. Lovegrove1, Nadine Shehab1
1Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States, 2Northrop Grumman Corporation (contractor to the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention), Atlanta, GA, United States, 3Eagle Contracting LLC (contractor to the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention), Atlanta, GA, United States

P46
Assessing Appropriateness Of Warfarin Care Plans Upon Referral To An Outpatient Anticoagulation Service
Elizabeth Renner, Erin Mouland, Samira Saad, Nghi Ha
University of Michigan, Ann Arbor, MI, United States

P47
Reasons For Discontinuation Of Direct Oral Anticoagulant Therapy In Patients With Non-Valvular Atrial Fibrillation
Elizabeth Renner1, Erin Mouland1, Samira Saad1, Nghi Ha1, Pauline Kim2
1University of Michigan, Ann Arbor, MI, United States, 2Indiana University Health, Indianapolis, IN, United States

P48
Concomitant Use Of Non-Steroidal Anti-Inflammatory Drugs And Direct Oral Anticoagulants
Quratulain Zulfiqar, Carolyn Combs, Kim Hall
Bay Pines Veterans Affairs Healthcare System, Bay Pines, FL, United States

P49
Providers&Rsquo; Perceptions Of Warfarin Dosing Nomograms
Trevor Gardner, Sara R. Vazquez, Aubrey E. Jones, Kibum Kim, Daniel M. Witt
University of Utah, College of Pharmacy, Salt Lake City, UT, United States

P50
Do Hospitalized Patients Receive Appropriate Venous Thromboembolism Prophylaxis?
Ankita Patel, Sarah Stuart, Valerie Allusson , Richard Adamczyk , Roveena Goveas, Mikita Patel, Sonia Ahmed, Ummi Khan
Hackensack Meridian Mountainsidehosp.com, Montclair, NJ, United States

P51
Implementation Of Anticoagulation Centers Of Excellence Standards To Improve Time In Therapeutic Range
Ashley M. Thomas1, Nilam Naik2, Bishoy Ragheb1
1VA Tennessee Valley Healthcare System, Murfreesboro, TN, United States, 2VA Tennessee Valley Healthcare System, Nashville, TN, United States

P52
Evaluation Of Apixaban And Rivaroxaban Utilization For Acute Venous Thromboembolism At A Western Michigan Community Teaching Hospital
Kristen Johnson, Josh Jacoby, Dan Boldt
Mercy Health Saint Mary's, Grand Rapids, MI, United States

P53
Adding Low Dose Vitamin K Supplements To Warfarin Regimen To Improve Poor Individual Time-In-Range Of International Normalized Ratio'S
Shelly A. Keune, Carol A. Abullarade, Bruce E. Burnett
Park Nicollet, St. Louis Park, MN, United States

P54
Prescribing Pattern Of Oral Anticoagulants In Patients With Obesity
Kristina Falk, Meghan McComb, Nancy L Shapiro, Ellen Uppuluri
University of Illinois, Chicago, IL, United States

P55
Disproportionate Anticoagulation And Opioid Keyword Frequencies In Hospital Regulations
Youssef Bessada1, Darren M. Triller2, Katherine P. Cabral1, Scott Kaatz3
1Albany College of Pharmacy and Health Sciences, Albany, NY, United States, 2WellScriptED Consulting Inc., Delmar, NY, United States, 3Wayne State University, Detroit, MI, United States

P56
Andexanet Alfa For Treatment Of Factor Xa Inhibitor-Related Acute Major Bleeding
Todd Fralich1, Truman John Milling Jr.2, Stuart J Connolly3, John Eikelboom3, C Michael Gibson4, Pamela B Conley1, Peter Verhamme5, Jeannot Schmidt6, Saskia Middeldorp7, Alexander T Cohen8, Jan Beyer-Westendorf9, Patrick Yue1, Andrew Demchuk10, Mark Crowther3
1Portola Pharmaceuticals, Inc., South San Francisco, CA, United States, 2Seton Dell Medical School Stroke Institute, Austin, TX, United States, 3Population Health Research Institute, McMaster University, Hamilton, ON, Canada, 4Harvard Medical School, Boston, MA, United States, 5University of Leuven, Leuven, , Belgium, 6Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, , France, 7Academic Medical Center, Amsterdam, , Netherlands, 8Guy's and St. Thomas' Hospitals, King's College London, London, , United Kingdom, 9University Hospital Carl Gustav Carus Dresden, Dresden, , Germany, 10University of Calgary, Calgary, AB, Canada

P57
Clinical Outcomes Following Administration Of 4F-Pcc For Management Of Bleeding Or Need For Emergent Procedure On A Xa Inhibitor - Good Enough, Or Do We Need Other Agents?
Maura K. Wychowski, Christina I. Ruscio, Ronald L. Sham, Peter A. Kouides
Rochester General Hospital, Rochester, NY, United States

P58
Effectiveness Of Antithrombotic Therapy-Related Transitions Of Care With A Focus On Interfacility Handoff Communication 
Chelsea Rodriguez1,2, Gabriel Garcia1,2, Gregory Hadlock1, Lisa Koselke1, Allison Burnett1,2
1University of New Mexico Hosptial, Albuquerque, NM, United States, 2University of New Mexico College of Pharmacy, Albuquerque, NM, United States

P59
Assessment Of The Knowledge About Venous Thromboembolism (Vte) On Pregnant Women Attending Kigali Referral Hospitals.
Christine ASHIMWE
Rwanda Clot Awareness Network, Kigali, Rwanda

P60
Venous Thromboemobism Risk, Prophylaxis And Outcome In Admitted Patients To The Medical Wards Of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia
Tamrat Assefa1, Feruza Ahmed1
1Addis Ababa University, Addis Ababa, Ethiopia, 2Addis Ababa University, Addis Ababa, Ethiopia

P61
Evaluation Of Clinical Effectiveness And Safety Of Direct Oral Anticoagulants: Qatar Registry On Direct Oral Anticoagulants (Qard-Registry)
Abdul Moqeeth Mohammed1, Abdelnasser Elzouki1, Ahmed Sobhy Mahfouz1, Hazem Elewa1, Eman El-Hamoud1, Osama Abdel-Samad1, Sumaya Mehdar Al Saadi1, Ezeldin Hamza Habab Soaly1, Rasha Zakaria Enany1, Muna A Qawi Al Bakri1, Naseer Masoodi1
1Hamad Medical Corporation, Doha, Qatar, 2Hamad Medical Corporation, Doha, Qatar, 3Hamad Medical Corporation, Doha, Qatar, 4Hamad Medical Corporation, Doha, Qatar, 5Hamad Medical Corporation, Doha, Qatar, 6Hamad Medical Corporation, Doha, Qatar, 7Hamad Medical Corporation, Doha, Qatar, 8Hamad Medical Corporation, Doha, Qatar, 9Hamad Medical Corporation, Doha, Qatar, 10Hamad Medical Corporation, Doha, Qatar, 11Hamad Medical Corporation, Doha, Qatar

P62
Real-World Assessment Of Off-Label Direct Oral Anticoagulant Dosing For Venous Thromboembolism
John A. Saunders, Whitney L. Gustafson, Sara R. Vazquez, Aubrey E. Jones, Daniel M. Witt
University of Utah, Salt Lake City, UT, United States

P63
Assessing The Accuracy Of International Classification Of Disease (Icd)10 Codes For Thromboembolic Events
Kevin F. Lawrence1, Christopher Joos2, Stacy A. Johnson3, Aubrey E. Jones4, Daniel M. Witt5
1University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, United States, 2University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, United States, 3University of Utah School of Medicine, Department of Internal Medicine, Salt Lake City, UT, United States, 4University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, United States, 5University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, United States

P64
Comparison Of Safety And Efficacy Of Enoxaparin Regimens For Treatment Of Venous Thromboembolism In The Setting Of Cancer
Katerina Bakhmut, Claresta Bergman, Vika Bursua, Jaclyn Ng
Jesse Brown VAMC, Chicago, IL, United States

P65
The Burden Of Hospital Readmissions For Venous Thromboembolism Among Acute Medically Ill Patients In The Us
Steven Deitelzweig1, Alpesh Amin2, Iwona Bucior3, Jay Lin4, Melissa Lingohr-Smith4, Brandy Menges4
1Ochsner Clinic Foundation, Department of Hospital Medicine and The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA, United States, 2University of California, Irvine, School of Medicine, Irvine, CA, United States, 3Portola Pharmaceuticals, South San Francisco, CA, United States, 4Novosys Health, Green Brook, NJ, United States

P66
A Targeted Change In Practice To Alleviate Emotional Harm Related To Venous Thromboembolism (Vte) At University Of Utah Health Care
Aubrey E. Jones1, Ryan Fleming2, Michael Feehan3, Stacy Johnson4, Daniel M. Witt1
1University of Utah College of Pharmacy Department of Pharmacotherapy, Salt Lake City, UT, United States, 2Thrombosis Clinic, University of Utah Health , Salt Lake City, UT, United States, 3Kantar LLC, San Francisco , CA, United States, 4University of Utah School of Medicine, Department of Internal Medicine, Salt Lake City, UT, United States

P67
Retrospective Review Of Catheter Directed Thrombolysis For Treatment Of Pulmonary Embolism
Anne Rose1, Josh DeGrave2, Matthew Williams2, Emily Zimmerman1
1UW Health , Madison, WI, United States, 2UW School of Pharmacy, Madison, WI, United States

5:30 - 6:30 PMGreat Hall 5
Point of Care Reception Symposium: How Evidence-Derived Clinical Decision Support within Electronic Health Records Can Improve Delivery of Optimized Anticoagulant Therapy: The Point of Care AC Decision Support Experience



Friday, April 12, 2019


7:30 - 8:15 AMGreat Hall 5
Centers of Excellence Breakfast Workshop (separate registration required)

8:00 - 8:30 AMGreat Hall 1-3
Continental Breakfast

8:30 - 10:15 AMGreat Hall 4
Session 3 Optimizing Anticoagulation Clinics

Chair(s): Diane Wirth and David Garcia
8:30
State Of Anticoagulation Management Services
Geoff Barnes
University of Michigan

9:05
Optimizing Warfarin
Nathan Clark
Kaiser Permanente Colorado

9:40
Practical Issues With Transitioning To Doac Clinic
Lynn Oertel
Massachusetts General Hospital

10:15 - 10:45 AMGreat Hall 1-3
Coffee Break

10:45 - 12:30 PMGreat Hall 4
Session 4 Controversies and Challenges in VTE

Chair(s): Steven Deitelzweig and Tracy Minichiello
10:45
Debate: Vte Treatment - Drug, Duration Dose
Arthur Allen
VA Salt Lake City Health Care System

10:45
Debate: Vte Treatment - Drug, Duration Dose
Michael Streiff
Johns Hopkins

11:20
Diagnostic Imaging Dilemmas In Vte
Marc Carrier
Ottawa Hospital Research Institute

11:55
Managing Vte In Cancer Patients
David Garcia
University of Washington

12:30 - 2:00 PMGreat Hall 5
Portola Lunch Symposium: REVERSAL OF SPECIFIC DIRECT ORAL ANTICOAGULANTS IN PATIENTS EXPERIENCING LIFE-THREATENING BLEEDS

12:30 - 2:00 PMGreat Hall 6
Roche Lunch Symposia: PT/INR Testing: Calibration, Correlation, Concordance

2:00 - 3:45 PMGreat Hall 4
Session 5 Moving the Needle - Creating Change at the National Level

Chair(s): Scott Kaatz
2:00
Update From Cms
Michelle Schreiber
Centers for Medicare and Medicaid Services

2:25
The Joint Commission New Patient Safety Goals
Andrew Bland
The Joint Commission

2:50
Update On The National Action Plan For Anticoagulant Adverse Drug Event Prevention&Mdash;Where Are We Now? 
Nadine Shehab
Centers for Disease Control and Prevention

3:05
Core Elements Of Anticoagulation Stewardship
Scott Kaatz
Henry Ford Hospital

3:45 - 4:15 PMGreat Hall 1-3
Coffee Break

4:15 - 5:55 PMGreat Hall 4
Session 6 Improving Safety and Quality in Anticoagulation Care

Chair(s): Michael Streiff and Stacy Ellsworth
4:15
Transitions Of Care
Allison Burnett
University of New Mexico Health Sciences Center

4:40
Bridging Difficult Cases
Elaine Hylek
Boston University School of Medicine

5:05
Shared Decision Making
Eva Kline-Rogers
University of Michigan

5:30
Clinically Important Drug-Drug Interactions
Sara Vazquez
University of Utah Health



Saturday, April 13, 2019


8:30 - 9:15 AMGreat Hall 5
Meet the Expert Breakfast (pre-registration required)

9:00 - 9:30 AMGreat Hall 1-3
Continental Breakfast

9:30 - 11:15 AMGreat Hall 4
Session 7 Cornucopia of Issues in Anticoagulation

Chair(s): Eva Kline-Rogers and Nathan Clark
9:30
Doac Reversal: Is It Necessary?
Mark Crowther
McMaster University

10:05
Focused Updates On Antithrombotics In Afib
Alan Jacobson
Loma Linda University Medical Center

10:40
Women'S Health And Anticoagulation
Bethany Samuelson Bannow
Oregon Health and Science University

11:15 - 12:30 PMGreat Hall 4
Session 8 WHAT IS THE AC PROVIDER TO DO? REAL-WORLD DILEMMAS - PRESIDENT PANEL

Chair(s): Sara Vazquez and Allison Burnett
Panelist
Mark Crowther
McMaster University

Panelist
David Garcia
University of Washington

Panelist
Scott Kaatz
Henry Ford Hospital

12:30 - 1:00 PMGreat Hall 4
Closing Remarks